The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven the biomedical community to action—to uncover and develop antiviral interventions. One potential therapeutic approach currently being evaluated in numerous clinical trials is the agent remdesivir, which has endured a long and winding developmental path. Remdesivir is a nucleotide analogue prodrug that perturbs viral replication, originally evaluated in clinical trials to thwart the Ebola outbreak in 2014. Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness.

中文翻译：

---

瑞德西韦：对其发现和开发的审查导致紧急使用授权用于治疗 COVID-19。

SARS-CoV-2（COVID-19 的致病病毒病原体）在全球大流行，促使生物医学界采取行动，发现并开发抗病毒干预措施。目前正在大量临床试验中评估的一种潜在治疗方法是瑞德西韦，它经历了漫长而曲折的发展道路。瑞德西韦是一种干扰病毒复制的核苷酸类似物前药，最初在临床试验中进行评估，以阻止 2014 年埃博拉疫情的爆发。随后众多病毒学实验室的评估表明，瑞德西韦具有抑制冠状病毒复制的能力，包括 SARS-CoV-2。在这里，我们概述了瑞德西韦的发现、作用机制以及当前探索其临床有效性的研究。